FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Denies Zydus Indomethacin Suppository Petition

FDA denies a Zydus petition asking the action to take actions about the indomethacin suppository reference standard.

latest-news-card-1
Human Drugs

9 Observations in Eugia Pharma Inspection

FDA releases the form FDA-483 with nine observations from an inspection at Indias Eugia Pharma Specialties sterile drug manufacturing facility.

latest-news-card-1
Biologics

Citius Pharma Refiles BLA for Lymphoma

Citius Pharmaceuticals resubmits a BLA for Lymphir (denileukin diftitox) for treating patients with relapsed or refractory cutaneous T-cell lymphoma.

latest-news-card-1
Human Drugs

FDA Approves Eicos Frostbite Drug

Regarding safety, the most common side effects of Aurlumyn include headache, flushing, heart palpitations, fast heart rate, nausea, vomiting, dizzines...

latest-news-card-1
Medical Devices

Smiths Medical Class 1 Recall of Syringe Pump

Smiths Medical ASD recalls its Medfusion model 4000 syringe pump due to issues associated with earlier software versions.

latest-news-card-1
Human Drugs

Guidance on Charging for Investigational Drugs

FDA posts a final guidance entitled Charging for Investigational Drugs Under an IND Questions and Answers.

latest-news-card-1
Federal Register

Drug Regulatory Site Tours Continue

Federal Register notice: FDA announces the continuation of its Regulatory Project Management Site Tours and Regulatory Interaction Program.

latest-news-card-1
Marketing

Panel Backs Abbotts TriClip PMA

An FDA advisory committee votes 13 to 1 that the benefits of Abbott's TriClip transcatheter edge-to-edge repair system outweighs the risks for treatin...

latest-news-card-1
Human Drugs

CDER OSI Annual Report

The CDER Office of Scientific Investigations (OSI) publishes its FY 2023 annual report with statistics on its consultations in the last fiscal year.

Human Drugs

CBER Safety Labeling Changes SOPP

CBER publishes a standard operating policy and procedure on Section 505 (o)(4) safety labeling changes to drugs approved by NDAs and BLAs.